KaloBios Pharmaceuticals, Inc. Initiates Phase 1/2 Trial of Humaneered(TM) Monoclonal Antibody KB001 for Treatment of Pseudomonas Infections in Mechanically Ventilated Patients

PALO ALTO, Calif.--(BUSINESS WIRE)--KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced the initiation of a Phase 1/2 clinical trial of KB001, a Humaneered™, high-affinity antibody fragment that KaloBios is developing for the treatment of Pseudomonas aeruginosa infections.